Table II.
Inhaled Antibiotic Formulations that are in Development or Commercially Available
| Brand | Active ingredient | Manufacturer | Product type | Status |
|---|---|---|---|---|
| Arikace™ | Amikacin | Insmed | Nebulizer | Phase III |
| BAY41-6551 | Amikacin | Bayer Healthcare/Nektar Pharmaceuticals | Nebulizer | Phase III |
| Cayston® | Aztreonam | Gilead Sciences | Nebulizer | Market |
| - | Capreomycin | - | DPI | Phase I |
| - | Ciprofloxacin | Bayer Healthcare | DPI | Phase III |
| Pulmaquin® | Ciprofloxacin | Aradigm | Nebulizer | Phase III |
| Colobreathe® | Colistimethate | Forest Laboratories | DPI | Market |
| Promixin® | Colistimethate | Profile Pharma | Nebulizer | Market |
| Aeroquin® | Levofloxacin | Aptalis Pharma | Nebulizer | Phase III |
| TOBI® | Tobramycin | Novartis | DPI, Nebulizer | Market |
| Fluidosome™ | Tobramycin | Axentis Pharma | Nebulizer | Market |
| Bramitob | Tobramycin | Chiesi Pharmaceuticals | Nebulizer | Market |
| AeroVanc™ | Vancomycin | Savara Pharmaceuticals | DPI | Phase II |